BMS’ Sotyktu (deucravacitinib) Receives EC’s Approval for the Treatment of Plaque Psoriasis
Shots:
- The approval was based on the P-III trials (POETYK PSO-1 & 2) evaluating Sotyktu (6mg, qd) vs PBO and Otezla in 666 & 1020 patients which showed superior efficacy in improving skin clearance @16 & 24wks. with responses maintained through 52wks.
- In both trials & time points, patients achieved an sPGA score of 0/1, PASI 75 & PASI 90 response while responses persisted through 52wk., 82% maintained their response at 52wk. in (POETYK PSO-1) trial who achieved PASI 75 at 24wk. while 80% who continued Sotyktu maintained PASI 75 response over 31% withdrew from Sotyktu in the (POETYK PSO-2) trial
- The (POETYK PSO) LTE trial's additional data also supported approval. The (POETYK) study program demonstrated a consistent safety profile at 3yrs. of continuous treatment
Ref: bristol-myers-squibb | Image: bristol-myers-squibb
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
